All In Biotech

Drug Trial Radar · NCT03032172

A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy

An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Risdiplam (RO7034067) in Adult and Pediatric Patients With Spinal Muscular Atrophy

Last checked: Nov 19, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

174

Actual

Start

Mar 3, 2017

Primary completion

Feb 7, 2025

Study completion Feb 7, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, exploratory, non-comparative, and open-label study to investigate the safety, tolerability, PK, and PK/PD relationship of risdiplam in adults, children and infants with Spinal Muscular Atrophy (SMA) previously enrolled in Study BP29420 (Moonfish) with the splicing modifier RO6885247 or previously treated with nusinersen, olesoxime or AVXS-101.

Conditions

  • Spinal Muscular Atrophy

Interventions

  • RisdiplamDrug

    Risdiplam will be administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Baseline up to 5 years
  2. Number of Participants Who Discontinued Treatment Due to AEsTime frame: Baseline up to 5 years
  3. Number of Participants With Shift in Puberty Status From BaselineTime frame: Baseline, Week 52, 104, 156, 208 and 260
  4. Number of Participants With Protocol-defined Neurological Conditions (NC)Time frame: Baseline up to Week 260
  5. Number of Participants With Emergence or Worsening of Symptoms as Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to approximately 5 years
  6. Anthropometric Examination: Change From Baseline in WeightTime frame: Baseline up to Week 260
  7. Anthropometric Examination: Change From Baseline in HeightTime frame: Baseline up to Week 260
  8. Anthropometric Examination: Change From Baseline in Head CircumferenceTime frame: Baseline up to Week 208
  9. Maximum Plasma Concentration (Cmax) of RisdiplamTime frame: Predose on Weeks 2, 4, 13, 26, 39, 52, 65, 91 and post-dose on Weeks 1, 4, 13, 52, 91 and 104
  10. Area Under the Concentration-Time Curve (AUC0-24h) of RisdiplamTime frame: 24 hours Postdose at Year 2 Visit
  11. Plasma Trough Concentration (Ctrough) of RisdiplamTime frame: Predose at Year 5 visit

Locations

24 sites in 9 countries. Site status is shown where the registry gives one.

  • Stanford University Medical Center

    Palo Alto, California

  • Nemours Children's Hospital

    Orlando, Florida

  • Boston Childrens Hospital

    Boston, Massachusetts

  • Columbia University Medical Center

    New York, New York

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Hopital Femme Mere Enfant

    Bron, France

  • Hopital Roger Salengro

    Lille, France

  • CHRU de Montpellier, Hopital Gui de Chauliac

    Montpellier, France

  • Hôpital Necker-Enfants Malades

    Paris, France

  • Hopital des Enfants

    Toulouse, France

  • Universitätsklinikum Essen

    Essen, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • IRCCS Ospedale Pediatrico Bambino Gesù

    Rome, Lazio, Italy

  • Policlinico Agostino Gemelli

    Rome, Lazio, Italy

  • IRCCS Istituto Giannina Gaslini

    Genoa, Liguria, Italy

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, Italy

  • UOSD Malattie Neurodegenerative

    Messina, Sicily, Italy

  • UMC Utrecht

    Utrecht, Netherlands

  • Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie

    Warsaw, Poland

  • Universitäts-Kinderspital (UKBB) Neuropädiatrie

    Basel, Switzerland

  • Birmingham Heartlands Hospital

    Birmingham, United Kingdom

  • UCL Institute of Child Health & Great Ormond Street Hospital for Children

    London, United Kingdom

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.